The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

BCL2 blunts activation of the mitochondrial pathway to apoptosis, and high-level expression is required for chronic lymphocytic leukemia (CLL) survival. Venetoclax (ABT-199) is a small-molecule selective inhibitor of BCL2 currently in clinical trials for CLL and other malignancies. In conjunction wi...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood
Main Authors: Anderson, Mary Ann, Deng, Jing, Seymour, John F., Tam, Constantine, Kim, Su Young, Fein, Joshua, Yu, Lijian, Brown, Jennifer R., Westerman, David, Si, Eric G., Majewski, Ian J., Segal, David, Heitner Enschede, Sari L., Huang, David C. S., Davids, Matthew S., Letai, Anthony, Roberts, Andrew W.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2016
Fag:
Lymphoid Neoplasia
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4920022/
https://ncbi.nlm.nih.gov/pubmed/27069256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-01-688796
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker